Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis

Daria M. Kartasheva-Ebertz¹,²*, Stanislas Pol¹,²,³ and Sylvie Lagaye¹

¹ Institut Pasteur, INSERM U1223, Paris, France, ² Université de Paris, Paris, France, ³ APHP, Groupe Hospitalier Cochin, Département d’Hépatologie, Paris, France

Despite all the medical advances mortality due to cirrhosis and hepatocellular carcinoma, the end stages of fibrosis, continuously increases. Recent data suggest that liver fibrosis is guided by type 3 inflammation with IL-17A at the top of the line. The storage of vitamin A and its active metabolites, as well as genetics, can influence the development and progression of liver fibrosis and inflammation. Retinoic acid (active metabolite of vitamin A) is able to regulate the differentiation of IL-17A+/IL-22–producing cells as well as the expression of profibrotic markers. IL-17A and its pro-fibrotic role in the liver is the most studied, while the interaction and communication between IL-17A, IL-22, and vitamin A–active metabolites has not been investigated. We aim to update what is known about IL-17A, IL-22, and retinoic acid in the pathobiology of liver diseases.

Keywords: IL-17A, retinoic acid, human liver fibrosis, chronic liver inflammation, fibrosis resolution

HIGHLIGHTS

• Type 3 inflammation (Th17, Tc17 cells) is involved in the process that guides liver fibrosis.
• Hepatic stellate cells activation is directly linked to the release of vitamin A from lipid droplets that are used as an important energy source for myofibroblast transformation, supported by autophagy.
• There are the SNP variants coding vitamin A metabolizing enzymes (PNPLA3, HSD17B13), associated with opposite prognosis in several chronic liver diseases.
• Immune modulation of the IL-17A/RA axis could be a new important component of the very active therapeutic developments of NASH and fibrotic disease.

INTRODUCTION

Liver fibrosis is the obligatory result of chronic liver disease, from which approximately 2 million people die each year (1). Despite all the medical advances, mortality due to cirrhosis and hepatocellular carcinoma (HCC), the end stages of fibrosis, continuously increases (2). The background of liver fibrosis involves multiple processes, including alcoholic lesions, chronic forms of viral hepatitis, and metabolic syndrome, which is becoming one of the most important causes today, a burden on our society. Western diets, reduced physical activity, and constant stress
all actively contribute to the dramatic increase in nonalcoholic steato-hepatitis (NASH) prevalence (3, 4).

The liver is known to be the main storage site for vitamin A and its derivatives. Vitamin A is a powerful antioxidant; its active metabolites directly regulate gene expression, participate in differentiation of IL-17A/IL-22 cells. Any impairment in retinoic acid (RA) metabolism probably affects the metabolic and immunological pattern of liver disease and, in particular, progression to fibrosis. Recent studies on the genetic substrate of liver diseases, particularly nonalcoholic fatty liver disease (NAFLD), have highlighted the presence of associated SNPs in genes that are involved in vitamin A metabolism. We propose to trace the interaction of three molecules (IL-17A, IL-22, RA) and assess the possible impact of this trio on the development of liver fibrosis. There may be a need to study the interaction of vitamin A metabolites and the immune component of the liver in the development of fibrosis, and this will provide new options for fibrosis treatment.

LIVER HOMEOSTASIS AND INFLAMMATION

The main causes of liver fibrosis are viral hepatitis, alcoholic, and nonalcoholic fatty liver disease, as well as cholestatic liver disease (1). If viral hepatitis could be controlled by anti-viral therapy and vaccination, alcoholic disease by abstinence from alcohol, the trends of recent years indicate a clear increase of the part of NAFLD in liver diseases and fibrosis, respectively. This is related to lifestyle factors, reduced physical activity, consumption of excessive amounts of fats and sugar, and great difficulty in changing lifestyle and habits, which is required in the treatment of this pathology (4).

In the genesis of liver disease, a huge role belongs to the development of chronic inflammatory response. The liver microenvironment determines the balance between tolerance and inflammation in the healthy organ (5). The blood carries large amounts of intestinal antigens detected by pattern recognition receptors (PRRs) located on liver resident macrophages (6) or hepatocytes (7) that have to be neutralized. After PRR stimulation, antigens are degraded silently, without usual secretion of pro-inflammatory cytokines (5). Such silent blood detoxification protects the body from massive activation of the immune system in response to microbes from the gut. In healthy subjects, such a process does not go beyond homeostasis. However, under the influence of various factors, the immunological hepatic tolerance is broken, followed by inflammation, and the tissue regeneration processes are disturbed. The hepatic stellate cells (HSC) lose lipid droplets of vitamin A and trans-differentiate into myofibroblasts (8), secreting extracellular matrix (ECM). The HSCs are located in the space of Disse, the space between hepatic trabeculae and sinusoids. The space of Disse is separated from the sinusoids by liver sinusoidal endothelial cells (LSECs). HSCs are the main cells responsible for the initiation of fibrosis, producers of extracellular matrix (9). In their inactive state, they express neuronal markers and are the main site of vitamin A storage in lipid droplets in the body. During activation, HSCs lose the expression of neuronal markers, as well as lipid droplets and transdifferentiate into myofibroblasts (8), cells with high proliferative and migratory potential. Myofibroblasts migrate to the site of inflammation and increase the expression of mesenchymal markers, such as α-SMA or type 1 collagen.

The massive and constant ECM production distorts the hepatic and vascular architecture leading to cirrhosis and hepatocarcinoma and may require liver transplantation. Although hepatocarcinoma may occur in the absence of advanced fibrosis stages (10).

In any case, inflammation precedes fibrosis. It appears that the branch of CD4 T-lymphocytes, the Th17 population (11), seems to be involved in the inflammation process that guides liver fibrosis and underlining liver pathologies (12–15). This branch is composed of Th17 CD3CD4+ or Tc17 CD3CD8+ cells, expressing the RORγt transcription factor (16), and secreting IL-17A alone or in combination with IL-22, as two signature cytokines of this population.

Biology of IL-17A

The main source of IL-17A is the Th17 CD4+ T lymphocytes (LTs) (11). Other cell populations may be involved: the CD8 (Tc17) LTs (17–19), double-negative LTs, LYT6, NKT cells, ILC3 cells, MAIT cells, monocytes, and even neutrophils (20). IL-17A expression in liver HSC cells has also been reported (21). IL-17A receptor (IL-17AR) expression is ubiquitous with the highest levels occurring in hematopoietic cells, while the major responses to IL-17A occur in epithelial, endothelial, and fibroblast cells (22). IL-17 receptor family includes five IL-17RA to IL-17RE receptor subunits. IL-17A signaling is mediated predominantly through the IL-17RA and IL-17RC subunits (23). In the liver, in addition to immune cells, IL-17AR expression has been detected on all types of hepatic cells, including hepatocytes, HSCs, biliary epithelial cells, and LSECs (24).

IL-17A activates a highly pro-inflammatory gene expression program, typical of that induced by innate immune receptors, such as IL-1R and TLRs (25), using the Act1 adapter instead of TRIF/Myd88, but similarly activates the nuclear factor κB (NFκB), MAPK, C/EBPβ pathways (22).

IL-17A is a driver of hematopoietic cell differentiation in the bone marrow to the granulocyte lineage by direct stimulation of granulocyte colony-stimulating factor (GM-CSF) expression by epithelial cells and STAT3 activation (26, 27). At the same time, IL-17A in cooperation with TNF-α stimulates the expression of adhesive molecules on endothelial cells, such as Selectin-E or ICAM-1, making possible enhanced granulocyte migration (28), which is increased by IL-8 secretion, that acts as an attractant for neutrophils (29, 30). A similar mechanism is involved in the initiation and development of liver fibrosis and is a part of carcinogenesis of certain tumors.

IL-17A neutralization is effective in psoriasis, rheumatoid arthritis, ankylosing spondylitis (31, 32), but not Crohn’s disease where it increases inflammation and susceptibility to fungal infections (33). Moreover, in the experimental autoimmune encephalomyelitis (EAE), an autoimmune model, not all Th17 cells have destructive autoimmune properties. Th17 generated under the influence of TGF-β1 and IL-6 produce IL-17A, and it does not induce autoimmune events without receiving additional stimulation by IL-23. However, Th17
generated under the influence of TGF-β3 do not need to receive IL-23 signal to be pathogenic. The molecular signature of these two Th17 populations is different (34). Neutralization of IL-23 improves liver fibrosis in the bile-duct ligation (BDL) mouse model (14). It turns out that the complete acquisition of the pathogenic function of Th17 is mediated by IL-23 rather than by TGF-β1 and IL-6 (35). All this suggests that IL-17A behaves differently depending on its tissue localization and the environment in which it acts.

**Biology of IL-22**

IL-22 is a cytokine of the IL-10 family, secreted by a vast majority of hematopoietic cells: Th17, Tfd, ILC3, NKT lymphocytes (36). Signaling occurs via the interferon family receptor IL-22R that binds with a second CRF2-4 component (IL10R2) shared with IL-10 (37, 38). An IL-22–binding protein (IL-22BP), a soluble molecule, binds IL-22 and blocks its interaction with the receptor complex, thereby preventing activation (39).

IL-22R is expressed on stromal and epithelial cells in various organs, including liver (36, 40); however, immune cells do not express it, and IL-22 does not appear to affect them (41). Downstream of the IL-22 receptor complex is the JAK-STAT pathway leading to the STAT1, STAT3, and STAT5 phosphorylation. In addition, IL-22 is capable of activating the three main MAPK pathways: the MEK-ERK-RSK, the JNK/SAPK, and the p38 kinase pathways (42). Unlike the majority of cytokines that target different cell types, the unique target of IL-22 is the non-hematopoietic cells of epithelia. IL-22 is a part of the established inflammation, but regulates tissue processes, a true regulator of epithelia.

**Retinoic Acid**

RA is an active metabolite of vitamin A which is liposoluble. Vitamin A is stored in its esterified form, retinyl esters, in the HSCs, which mainly trigger liver fibrosis after activation. Retinaldehydes catalyze the release of active metabolites of vitamin A (Figure 1), including RA (43, 45). Vitamin A is distributed to tissues in the form of retinol, by retinol binding protein 4 (RBP4), produced in the liver. RA regulates the expression of several hundred genes, and this is what provides most of its functions (45). RA acts through nuclear receptors: RA receptors (RARα, β, γ) and retinoid X receptors (RXRα, β, γ). The receptors form homo- or heterodimers and exert their action by binding with the RA response element (RARE) in the promoters of regulated genes (46).

Despite the storage of vitamin A in the liver, RA plays a critical role in the regulation and maintenance of intestinal epithelium on the one hand (47), and mucosal immunological function on the other (48). NAFLD is directly related to a permeability disorder of the intestinal epithelium. Disruption of vitamin A metabolism and RA signaling will affect both hepatic functionality and intestinal integrity, creating a vicious circle of events (43). It is still unknown exactly what is primary and to what extent disruption of vitamin A metabolism impacts the immunological environment in the liver, the metabolic environment, and would promote the progression of liver fibrosis.

RA is known to influence FoxP3+ Tregs and Th17 differentiation, to induce intestinal homing of innate lymphoid cells (ILC) (49), to stimulate the secretion of pro-inflammatory cytokines during infections, and in synergy with dendritic cells to sensitize effector lymphocytes (50, 51).

---

**FIGURE 1** | Metabolism of vitamin A in the liver. Schema modified from Blaner, 43 and Pettinelli et al., 44. LRAT, lecithin retinol acyltransferase; DGAT, diglyceride acyltransferase; ADH1A, alcohol dehydrogenase 1A; AKR1B10, aldo-keto reductase family 1 member B10; BCMO1, beta-carotene monooxygenase; ALDH1A, aldehyde dehydrogenase 1 family member A; RBP4, retinol binding protein 4.
Th17 Differentiation: The Role of RA

Th17 cells are considered to be the main source of the cytokines IL-17A and IL-22 (52). The differentiation and expansion of Th17 from naive LTs are dependent on two cytokines: TGF-β1 and IL-6 (Figure 2). This process is regulated by IL-23 and IL-21 (52). High concentrations of IL-6, secreted by macrophages, in its STAT3-dependent manner will activate HIFα, which in turn will target FoxP3 for ubiquitination and proteasomal degradation (53), promoting the expression of the RORγt factor and the Th17 branch (54). Low concentration of TGF-β1 in cooperation with IL-6 will induce the development of Th17s and the expression of the IL-23R receptor (54), while a high concentration in the absence of IL-6 will promote the iTreg lineage (53). This Treg/Th17 counterbalance is used in research as a marker of type 3 inflammation. IL-23, which belongs to the IL-12 family of cytokines, acts as a stabilizer that is essential for the correct development of Th17 (55). During inflammation IL-23 is produced by activated dendritic cells and, by acting on T lymphocytes, increases IL-17A secretion (56).

In addition to IL-6, TGF-β1, and IL-23, the expression of IL-17A is regulated by retinoids, in particular RA (Figure 2), which is important in the context of liver disease and fibrosis, since the liver is the main site of storage of Vitamin A. RA is capable of inhibiting the expression of RORγt, promoting the development of iTregs and the expression of FoxP3. This occurs in an independent manner of STAT3/STAT5 and IL-2 signaling (57, 58). Schambach et al. provided evidence that the effects of active vitamin A metabolites are likely to be at least partially mediated by the nuclear RARα (59). Moreover, RA induces IL-22BP expression in monocyte-derived dendritic cells. In addition to direct regulation of Th17 cells formation, RA separately regulates the action of IL-22 (60).

In in vitro models, RA is very efficient in the generation of iTregs despite Th17 (61). RA enhances TGF-β1-signaling by increasing SMAD-3-dependent FoxP3 expression even in the presence of IL-6 (61). However in vivo there is no increase in the frequency of iTregs, whereas RA suppresses the EAE by inhibiting the inflammatory action of Th17 through the inhibition of IL-6Ra, IL-23R, and interferon regulatory factor 4 (IRF-4) receptor expression on effector T cells (61).

Genetic Associations, Vitamin A, and Chronic Liver Diseases

Analysis of gene expression involved in vitamin A metabolism showed that aldo-keto reductase family 1 member B10 (AKR1B10), the enzyme converting all-trans-retinaldehyde to retinol (Figure 1), is up-regulated in NASH patients compared with healthy controls, which is associated with elevated blood retinol levels (44). In contrast, the enzymes known to convert retinaldehyde to RA: aldehyde dehydrogenase 1 family member A (ALDH1A1, ALDH1A2, ALDH1A3), exhibit decreased expression in NASH patients (44)-(62). However, CYP26A1 and CYP26B1 expression is enhanced in NASH patients, indicating more intensive degradation of RA (62).
Consequently, this impairs the availability of active vitamin A metabolites in the liver, particularly RA, altering the functioning of signaling pathways.

Borel and Desmarchelier, 2017 have reviewed genetic variations thought to be associated with modulation of vitamin A blood levels (63). These include mutations and SNPs in RBP4, beta-caroten oxygenase 1 (BCO1), scavenger-receptor class B 1 (SCARB1), APOB, CXCL8, CD36, and other genes. For the moment, there are just some variants in genes that encode important enzymes, associated with the progression of chronic liver diseases, particularly the progression of NAFLD to fibrotic or cirrhotic liver and HCC (64) (reviewed by Carlsson, 2020). Some of them are presumably involved in vitamin A metabolism.

PNPLA3 is a member of a family of patatin-domain containing lipid hydrolases, localizes to the surface of lipid droplets, with multiple substrates, including triacylglycerols, phospholipids and retinols-esters, the storage form of vitamin A. PNPLA3 is thought to be involved in release of retinol in response to insulin from HSC (65), an important step of HSC activation. The first SNP found to be associated with NASH progression to advanced fibrosis or HCC is PNPLA3 I148M variant, associated with decreased enzymatic activity, increased hepatic fat storage, progression of steatohepatitis, elevated plasma liver enzymes, fibrosis. At the same time, in PNPLA3 I148M minor allele carriers, the storage of liver retinyl-palmitate is increased, and the ratio of retinol/retinyl-palmitate is reduced (66), which reveals a disturbance in the vitamin A metabolism and signaling. PNPLA3 I148M SNP carriers with obesity and fatty liver disease or who are just obese, have lower levels of circulating retinol, as well as RBP4 protein concentration (67). Meanwhile, Blaner questions the hydrolase activity of PNPLA3, arguing for insufficient data (43). This needs to be explored.

HSD17B13 is the second protein of interest with restricted expression for hepatocytes, which belongs to the short-chain dehydrogenase/reductase family, involved in the metabolism of steroid hormones, prostaglandins, lipids, and xenobiotics. Biological function of HSD17B13 is not clear: when overexpressed, the size and number of lipid droplets in hepatocytes is increased (68), but this remains debated (69). Meanwhile, hepatic expression of HSD17B13 is higher in NASH patients compared with healthy individuals (70). P260S mutation (rs62305723) in HSD17B13 gene, abolishing retinol dehydrogenase activity in vitro, is associated with decreased inflammation and ballooning (70). Another loss-of-function variant in HSD17B13 (rs72613567:TA) was found to be associated with a reduced risk of chronic liver disease, like alcoholic and non-alcoholic chronic liver diseases, reduced risk of progression from steatosis to steatohepatitis, but not simple steatosis, as well as reduced risk of alcoholic and non-alcoholic cirrhosis in allele dose-dependent manner (69) [71]. However, an attempt to replicate the protective effect in the whole body knock out (KO) for HSD17B13 murine model failed. No difference was observed between the KO model and the wild type (WT) genotype neither in the severity of liver damage due to a high-fat diet or alcohol consumption model nor in the rate of disease progression to cirrhosis and hepatocarcinoma (72).

### IL-17A, IL-22, AND RA IN LIVER FIBROSIS

Fibrosis is a two-way process, capable of regressing even in advanced stages (73). Liver fibrosis of any etiology predisposes to the development of hepatocarcinoma (74), which may also occur on a background of chronic inflammation without advanced fibrosis (75, 76). The exact immunological mechanisms that direct the development or regression of fibrosis, or development of hepatocarcinoma without adjacent fibrosis, are not well elucidated.

### IL-17A, IL-22, and Acute Liver Injury

#### IL-17A

During acute liver injury Kupffer cells, found in the sinusoids and secreting platelet derived growth factor (PDGF), TNFα, IL-6, IL-1β, TGF-β1 (77), stimulate STAT3 signaling in HSCs. HSC awaken from their quiescent state, release their vitamin A stock and transform into myofibroblasts, which migrate to the site of injury (8). In the injury, INFγ, the potent STAT1 activator, secreted by intrahepatic T cells, induces apoptosis of damaged/infected hepatocytes amplifying the inflammatory signal (78, 79). While IL-6-directed response, ensured by STAT3 expression in myeloid cells, protects against liver damage by counteracting INFγ-signaling (80). Meanwhile the promotion of STAT3 expression under TGF-β1 and IL-6 also stimulates the Th17 phenotype. IL-17A can stimulate STAT3 phosphorylation directly (in vitro) or via enhancing IL-6 secretion (81). In the case of acute viral diseases, IL-17A, on the one hand, can sensitize antigen-specific effector T cells (82), promoting the elimination of the agent, on the other hand, an exhaustive IL-17A and IL-6 response can promote viral persistence (83).

IL-17A neutralization aggravates the development of acute hepatitis in a galactosylceramide model directed by IL-17A+NKT cells (84). Similarly, TyβIL-17A−-depleted HBs transgenic mice during the concanavalin A (ConA) lesion, develop inflammation exacerbated by INFγ and accompanied by potent necrosis. Injection of IL-23 decreased liver damage (85). However, in WT mice in the ConA model, IL-17A produced mainly by Th17, aggravates liver damage (86), but macrophage depletion prevents the development of lesions, at least in part, by interrupting IL-17A signaling. Moreover, it was shown that in the early stage of liver injury, exosome-mediated TLR3 activation in HSCs aggravates the development of liver fibrosis by enhancing IL-17A Tγδ-cell production in CCl4 mouse fibrosis model. HSCs express IL-17A cytokine, and this secretion is TLR3-dependent. TLR3 is activated by an unknown ligand from hepatocyte exosomes (Table 1) (21).

#### IL-22

Transgenic IL-22− mice are highly susceptible to increased development of acute hepatitis, and their regenerative processes are delayed (87). The same applies to IL-22BP-deficient mice in a model of toxic hepatitis (88). In a model of acute liver injury (induced by LPS/d-galactosamine), treatment with recombinant IL-22 (rIL-22) has a protective effect due to its anti-apoptotic, anti-inflammatory, and antioxidative effects (89). The same was found for ILC3RORγT+IL-22+ cells (90). IL-22...
overexpression significantly increases the expression of the anti-apoptotic genes Bcl2, Bcl-xL and the STAT3-p53 axis, induces HSCs senescence, and thus protects the liver from injury in ConA, carbon tetrachloride (CCl4) or Fas agonist models (91–94). In a mouse model of acute ethanol-induced injury, treatment with rIL-22 improved alcoholic steatosis, tissue damage, and oxidative stress via STAT3 activation (95); and rIL-22 inhibited HSCs activation in vitro (96). All this points rather to the protective side of IL-22 during acute liver injury, directed towards tissue regeneration (Table 2).

**IL-17A, IL-22, and Chronic Liver Injury**

If the damaging factor is eliminated, the inflammatory process shifts to regeneration, and, in addition to the regenerative signal provided by IL-22, the switch in macrophage phenotype from pro-inflammatory to pro-fibrotic downstream of the inflammatory response has been reported (109). If the damaging factor (metabolic syndrome, alcohol abuse, chronic viral infection, auto-immune disease) persists, the inflammatory process results in fibrosis instead of regeneration. The sustained inflammation leads to perpetual activation of the HSCs, which undergo a myofibroblast phenotypic transformation: they secrete the components of the extracellular matrix (8). Since MMPs are blocked by the overexpression of tissue inhibitor of metalloproteinases (TIMPs), the matrix invades the damaged tissue. The role of IL-17A appears to be crucial in chronic liver inflammation (Table 3). The pro-fibrogenic role of IL-17A has also been reported in pulmonary (111) and intestinal fibrosis (112).

### Table 2 | IL-17A in acute liver injury.

| Model | Cells | Action | Reference |
|-------|-------|--------|-----------|
| HepG2 cell line | Cytotoxic LT CD8 | STAT3 phosphorylation enhances IL-6 secretion | Hu et al. (81) |
| Viral Infection West Nile Fever (WNV) in IL-17A−/− mice | Cytotoxic LT CD8 | Reduced survival of WNF IL-17A−/− mice IL-17A sensitizes antigen-specific effector T cells | Acharya (82) |
| Susceptible mice with Theiler's murine encephalomyelitis virus | NKT IL-17A+ | Exhaustive IL-17A response promote viral persistence | Hou et al. (83) |
| α-Gaucher-induced acute hepatitis in mice | LTδ IL-17A−/− Th17 | Protective role, produced IL-17A inhibits the development of hepatitis. | Wondimu et al. (84) |
| HBsTg mice ConA lesion | LTδ IL-17A−/− Th17 | Protective, IL-23 mediated role, ameliorated liver damage in HBsTg mice | Meng et al. (85) |
| WT mice ConA lesion | IL-17A+ | IL-17A aggravates liver damage | Yan et al. (86) |

### Table 2 | IL-17A in chronic liver injury.

| Model | Cells | Action | Reference |
|-------|-------|--------|-----------|
| Mice | Th17, neutrophils IL-17A−/− | Neutrophile influx, inflammation, fibrosis reduction in IL-17A−/− deficient mice | Tan et al. (15); Meng et al. (14) |
| CCl4-induced fibrosis in TLR3-deficient mice | LTδ IL-17A−/− Th17 | Enhanced IL-17A production by LTδ TLR3-mediated IL-17A neutralization improved BDL-induced fibrosis | Seo et al. (21); Zhang et al. (97) |
| BDL-induced model of liver fibrosis, cholestatic model | LTδ IL-17A−/− Th17 | Periportal-bridging fibrosis, increased numbers of LTδ IL-17-A−/− | Tedesco et al. (98) |
| MDR-/- mice, cholestatic model | LTδ IL-17A−/− Th17 | Higher frequency of liver Th17 cells compared to normal diet; inhibition of fatty acid oxidation, steatosis exacerbation | Tang et al. (99); Shen et al. (100) |
| C57BL/6 mice on high fat diet | CD4+IL-17A+ Th17 | IL-17A production exacerbated obesity-induced hepatic cellular damage. | Harley et al. (101); Giles et al. (102) |
| IL-17A-deficient mice + high fat diet | CD4+IL-17A+ | Inflammation, NASH progression, liver fibrosis | Her et al. (103) |
| Humanized mice on high fat diet | CD4+IL-17A+ | Neutrophils IL-17A−/−, CD45+IL-17A−/− infiltration of human liver tissue, independent of fibrosis stage. | Macek et al. (104) |
| Chronic HBV+ patients, human liver samples, immunohistochemistry staining | neutrophils IL-17A- CD45 IL-17A+ | Increased IL-17A expression in advanced fibrotic stage, increased CD4+IL-17A+ infiltration | Fabre et al. (105); Zhang et al. (12); Tan et al. (13); Wang et al. (106); Zhang et al. (107) |
| Chronic HBV+ patients, Human liver biopsies, immunohistochemistry staining, Flow Cytometry | CD4+IL-17A+ | Increased IL-17A expression in advanced fibrotic stage, increased CD4+IL-17A+ infiltration | Fabre et al. (105); Zhang et al. (12); Tan et al. (13); Wang et al. (106); Zhang et al. (107) |
| NASH patients | IL-17A+ cells | Increased Th17 infiltration, IL-17A association with hepatic steatosis and proinflammatory response in NAFLD | Tang et al. (99); Rau et al. (108) |
This may be due to NLRP3 inflammasome inhibition (116). In turn, HSCs stimulated by IL-17A increase the secretion of IL-6, TGF-β1, collagen production, α-SMA expression, all markers of HSCs activation (15). However, IL-17A rather sensitizes HSCs for TGF-β-signaling by regulating TGF-β2-receptor expression and does not activate them directly (117). The same was seen in the BDL model (97). Cholestatic mice mdr−/− model shows increased infiltration of the liver by LTβR−/−IL-17A−/+ (98).

A pro-fibrotic and pro-inflammatory role of IL-17A was shown in the NASH mouse model (99, 100). The use of IL-17A−deficient mice models has been shown to improve/resist to the development of steatohepatitis, a major risk factor of fibrosis (101, 102). Humanized mice on high fat diet with induced NAFLD develop liver fibrosis that is mediated by CD4+ IL17A+ cells (103). The depletion of CD4+ cells in these mice reduced fibrosis and inflammation but not steatosis. Moreover, in human liver, an increase in the number of IL-17+ cells, among intrahepatic CD4+ cells, was observed during the transition of NAFLD to NASH. Th17/Treg ratio was significantly higher in NASH patients, and the Tregs count, on the contrary, was much lower (108).

In patients with chronic viral hepatitis, neutrophils accounted for most of the IL-17A+ cells, especially in the late fibrosis stage, but the frequency of CD45+IL-17A+ lymphocytes in liver tissue was independent of the stage of fibrosis (F0–F3) (104). However, an increase in IL-17A expression has been shown in the advanced stages of HBV-related liver disease by the immunohistochemistry on fresh biopsies of HBV+ patients (12, 15, 105–107) or patients with non-alcoholic steatohepatitis (99).

IL-17A induces autophagy and may promote the development of hepatocarcinoma (118). Zhang et al. (2017) demonstrated that the resolution of BDL- or thioacetamide-induced inflammation and fibrosis after IL-17A neutralization is due to a shift of the “suppressive” immune response in the fibrotic liver toward a Th1-type response, via restoration of autophagy activity through inhibition of STAT3 signaling (97). In addition, activation of autophagy in Kupffer cells decreases liver fibrosis via suppression of IL-1β expression (119).

**IL-22**

The impact of IL-22 on fibrosis development in chronic liver injury is much more ambiguous (Table 4). Since IL-22 promotes survival and proliferation of epithelial cells and shows its protective properties during acute injury, its role differs depending on the duration and progression of the disease. IL-22 is unable to inhibit hepatitis B virus replication, and its neutralization in a model of HBV transgenic mice improved liver damage (12). At the same time, study on pulmonary fibrosis showed lungs infiltration by TγβIL-22+ lymphocytes with protective anti-fibrotic potential (127). IL-22 injection protects mice against BDL-induced liver fibrosis (14). In CCl4-induced liver fibrosis, IL-22 is capable to slow liver fibrosis progression via an increase in anti-inflammatory KCS to pro-inflammatory-KCs ratio (120). However, IL-22RA1 knock-out mice develop mild fibrosis in response to CCl4 treatment, and IL-22/IL-17 inhibition leads to reduced fibrosis (105).

IL-22 shows protective traits in mice models of NASH pathology, but only in the absence of IL-17A (122). CXCL1, which regulates reactive oxygen species release by neutrophils and stress kinase activation in a mouse model of NASH, can be altered by IL-22, attenuating NASH progression (121). Recent study has demonstrated that IL-22 is capable to increase lipid metabolism in the liver and have anti-apoptosis activity (123).

Acting through STAT3 activation, IL-22 promotes hepatocyte proliferation and survival, increases HSC senescence (93). As a consequence, chronic inflammation and strong IL-22 signaling, constitutive activation of STAT3, upregulation of anti-apoptotic genes, vascular endothelial growth factor (VEGF) expression, all these factors promote and enhance the development of hepatocarcinoma (128).

Immunohistochemistry analysis of human biopsies shows significant IL-22+ cell infiltration in HBV+ patients with liver cirrhosis (105) (129). Moreover, systemic level of IL-22 is predictive of survival in cirrhotic HBV+ patients (130). The high expression of IL-22 in HBV+ patients has been found to promote fibrosis progression by inducing intrahepatic migration of Th17 cells via decreased hepatic expression of CXCL10 and CCL20 (124). Also, the pro-fibrotic function of IL-22 is associated with an enhancement of TGF-β1-signaling in HSCs in a p38 protein kinase-dependent manner (105). Meanwhile, IL-22 was protective in chronic hepatitis C and schistosomiasis infection, the high level of IL-22BP was associated with aggravation of hepatic fibrosis (125). However, another team showed worsening effects of IL-22 in HCV-infected patients, as

**TABLE 3 | IL-22 in acute liver injury.**

| Model | Cells | Action | Reference |
|-------|-------|--------|-----------|
| TgIL-22+ mice | Th17 IL-22+ | Susceptible to the enlarged development of acute hepatitis, protective role of IL-22 | Zenewicz et al., (87) |
| Acetaminophen-Induced liver injury, toxic hepatitis | IL-22BP-deficient mice | Susceptible to the enlarged development of acute hepatitis, protective role of IL-22 | Kleinschmidt et al., (88) |
| LPS/d-Gal, rIL-22 treatment | ILC3RORγTLIL-22+ cells | Anti-apoptotic, anti-inflammatory, and antioxidant actions | Xing et al., (89) |
| CCl4 acute liver injury | Th17, Th22, Th1 | Protective role of IL-22 via the induction of HSC senescence. | Kong et al., (93); Lu et al., (94) |
| LPS/d-Gal, rIL-22 treatment | LTCD3+ lymphocytes | protective role of IL-22 via STAT3 activation | Radaeva et al., (110); Pan et al., (91) |
| Ethanol-induced injury | Th17 | Improved liver damage, steatosis via STAT3 activation | Ki et al., (95) |
manifested by increased infiltration of IL-22+ cells, colocalized with α-SMA protein of HSCs in the advanced stages of fibrosis (126).

**Interplay Between IL-17A, IL-22, and RA**

The differentiation of the main source of IL-17A and IL-22, the Th17 cells, is dependent on RA signaling. The major cells involved in the production of fibrosis, the HSCs, are a major source of vitamin A, a storage form of retinyl esters packed in lipid droplets.

**RA and HSCs Activation**

HSCs activation is directly linked to the release of lipide droplets with vitamin A storage, which they use as an important energy source for their activation, supported by autophagy, which is a major source of free fatty acids and fuels the activation of HSCs (8). LPS flow enhances autophagy activation and deregulates retinoid signaling (131). During the first phase of HSCs activation, the lipid droplets decrease in size and migrate to the newly formed cell expansions. Retinyl esters in the lipid droplets are replaced by triacylglycerol species. In the second phase, the remaining lipid droplets decrease in size and undergo degradation (132). According to the limited number of studies, lysosomal lipase (LIPA) as well as PNPLA3 have retinyl-esterase degradation (132). According to the limited number of studies, lysosomal lipase (LIPA) as well as PNPLA3 have retinyl-esterase degradation (132). The absence of retinoid stockage does not enhance liver fibrosis in BDL or CCl4 mice models (134). However, it was discovered that exosome-derived long non-coding RNA-H19 (IncRNA-H19) enhanced RA signaling, which was manifested in increased HSCs activation, increased retinol metabolism, and decreased number of lipid droplets in HSCs (134, 135). Moreover, ADH3 is an important link in this activation, because its inhibition leads to disruption of IncRNA-H19/RA signaling and to HSCs’ inactivation. The role of exosomes in HSCs activation is much more ample and perfectly reviewed by Chen (135). Thus, the explicit role of retinoid lipid droplets and active vitamin A metabolites during HSCs activation remains open.

**RA and Liver Pathology**

A decrease in total retinol and an increase in RA were found in the liver of rats treated with CCl4 or thioacetamide (136). RA down-regulates fibrosis markers expression in a rat model of alcoholic liver disease, enhancing the abstinence effect (137).

In patients with NASH or NAFLD (or type 2 diabetes), the serum RA concentration is significantly lower than that in healthy subjects (136) (138). Histologically, the expression of RXRα RNA was inversely correlated with the stage of liver steatosis (138). The protective effect of RXRα is likely to be related to the synergy of action with the PPARγ receptor (139–141). The analysis of vitamin A metabolome in human livers with NASH showed disrupted vitamin A homeostasis, potentially contributing to disease progression. Interpretation of retinoid homeostasis on the basis of indirect markers such as retinol concentrations or mRNA data is probably misleading (142).

**RA and IL-17A Interactions**

On the one hand, RA enhances TGF-β1 signaling in T lymphocytes, through increased expression and phosphorylation of the transcription factor SMAD3 (61). On the other hand, RA downregulates TGF-β1/Smad3 signaling, IL-6 and collagen expression in the tissue parenchyma (131, 143). This results in the decrease of HSCs proliferation and fibrogenic gene expression (144). During liver fibrosis, these are key molecules upregulated by IL-17A, thus it can be speculated that disruption of RA signaling will extend the deleterious effects of IL-17A.

RA interacts with different immune populations, which are involved in the development of liver fibrosis. It upregulates RAE1 expression, NK cell-activating ligand expressed on HSC. NK cells proceed to cytotoxicity and thus regulate the number of formed myofibroblasts (110, 145). On the one hand, RA inhibits IL-17A secretion in cultured Th cells stimulated by IL-1β and IL-23 and in infected mice (autoimmunity model), but does not affect INFγ

---

**TABLE 4 | IL-22 in chronic liver injury.**

| Model | Cells | Action | Reference |
|-------|-------|--------|-----------|
| Mice  | HBV* Tg mice, IL-22 neutralization BDL-induced fibrosis CCL4 -induced fibrosis CCL4 -induced fibrosis CXCL1/High Fat Diet-induced NASH NASH model (mice fed methionine choline-deficient diet) NASH model (high fat diet) ILC3KO mice | IL-22 neutralization improves liver damage IL-22 can increase the ratio of M2/M1, protective role of IL-22 IL-22 deleterious effects on liver fibrosis IL-22 blocked hepatic oxidative stress, via induction of the antioxidant proteins. Inhibited inflammation in NASH IL-22 is protective in NASH but only in the absence of IL-17A IL-22 enhances hepatic lipid metabolism, and have anti-apoptosis activity | Zhang et al. (12) Meng (14) Su et al. (123) Fabre et al. (105) Hwang et al. (121) Rolla et al. (122) Hamaguchi et al. (123) |
| Human | HBV* patients, liver cirrhosis HCV* patients HCV* patients | IL-22+ cells Th17 IL-22BP IL-22+ cells IL-22+ cells IL-22+ cells ILC3ROαγt+IL-22+ cells | Increased IL-22+ cell infiltration, correlation with advanced stages, cirrhotic liver IL-22-BP aggravates liver fibrosis in HCV infection, protective role of IL-22 Increased IL-22+ cell infiltration depending on fibrosis stage | Fabre et al. (105); Zhao et al. (124) Sertorio et al. (129) Wu et al. (129) |
secretion (146). On the other hand, under the influence of RA, Tγδ lymphocytes can secrete large amounts of IL-22, which promotes the affinity of the RAR receptor to the IL-22 promoter, thus reducing inflammation (147, 148). RA also improves liver damage in a T-cell-mediated mouse model by reducing INFγ secretion by NKT cells, but does not affect their activation (149).

RA decreases the expression of IL-6, IL-23, and IRF-4 receptors in vitro (61). This implies that even in the presence of IL-6 and IL-23, there is an increase in Foxp3+ Tregs and inhibition of IL-17A, which can lead to a decrease in neutrophil inflow to the site of inflammation. In in vivo EAE models, RA does not increase the frequency of Treg, but was able to inhibit inflammatory response of Th17 cells (61). Lymphocytes T previously treated with RA are no longer able to induce EAE in mice, there is a decrease in the infiltration of the central nervous system by IL-17A+ T cells (146). Moreover, vitamin A supplementation has been shown to decrease RORγt and IL-17A expression in multiple sclerosis (150).

Another team reports a decrease in liver damage in the cholestatic mouse model (BDL) after treatment of mice with ursodeoxycholic acid (UCDA), the only drug approved for the treatment of liver cholestasis, in combination with RA (151). RA alone or in combination with UCDA significantly reduced the expression of TGF-β1, Col1A1, MMP-2, α-SMA, CYP7A1, TNFα, and IL-1β (151). The same results were seen in the murine model of hepatic fibrosis CCl4, administration of RA decreasing TGF-β1 and IL-6 secretion and increasing survival (152).

IL-17A activates the expression of the MMP-2 and MMP-9 in vitro (153), which are widely implicated in the progression of liver fibrosis (154). RA, for its part, is able of reversing this activation, thus moderating the spread of the pathological process (fibrosis or cancer) (155). In a rat model of alcoholic liver disease, RA treatment downregulated MMP-2 and MMP-9 expression, as well as TIMPs expression (137), but could enhance MMP-3 and MMP-13 expression in HSC rat cell line (144). In addition RA can promote the upregulation of MMPs in dendritic cells (156) or mesenchymal stem cells (157) causing their enhanced migration to the site of injury.

**CONCLUSIONS**

There is much evidence of the deleterious effects of IL-17A on the development of a liver disease, particularly liver fibrosis. Regardless of regeneration or fibrosis, the liver responds to

---

**FIGURE 3** | Trio IL-17A/RA/IL-22 in development of liver fibrosis. Under the influence of damaging factors there is an activation of the intrahepatic immune system guided by IL-17A, TGF-β1 and IL-6. Under TGF-β1 and IL-6 secreted by Kupffer cells, as well as IL-17A secreted by Tγδ, Th17, myeloid populations, there is an activation of HSC. Upon activation, the HSC releases lipid droplets filled with retinyl esters and transforms into myofibroblasts, generating the extracellular matrix, notably collagen. IL-17A promotes the migration of circulating immune cells, RA is able to disrupt IL-17A, TGF-β1 and IL-6 signaling by inhibiting the expression of IL-6 receptors, thereby moderating HSCs activation. Fibrosis progression is associated with permanent remodeling of the deposited matrix. RA is capable of inhibiting MMP-2, MMP-9, certain TIMPs, and thus moderating the spread of fibrosis. Through STAT3 activation IL-22 contributes to hepatocyte proliferation, differentiation and migration. HSC, hepatic stellate cell; RA, retinoic acid; ECM, extracellular matrix; MMP, metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; ILC3s, type 3 innate lymphoid cells; MAITs, mucosal associated invariant T cells. Red arrows—possible inhibitory effect, Green arrows—possible activator effect.
damage by activating HSCs that release their vitamin A stores. Active metabolites of vitamin A, such as RA, are strongly involved in the differentiation of the Th17 cell population, the main producers of IL-17A and IL-22. As a result of its anti-inflammatory and immunomodulatory effects, RA can down-regulate the secretion of IL-17A by immune cells and promote IL-22 signaling. However, very few studies have examined the relationship of this IL-17A-AR-IL-22 trio in the context of liver fibrosis.

In addition to a role in the immune component, genetic variations in enzymes, regulating the availability of active Vitamin A metabolites in the liver, have been found. These SNPs affect the prognosis of the course of chronic liver disease, like alcoholic and nonalcoholic liver diseases. In animal models, RA is able to inhibit IL-17A secretion, IL-6R, IL-23R expression, regulate MMPs/TIMPs and TGF-β1 expression, and thus regulate the development of inflammation and fibrosis (Figure 3). The data suggest that the concentration of RA in the liver increases progressively as fibrosis progresses and decreases in the serum. This, on the one hand should alleviate IL-17A-associated inflammation, but, on the other hand means a high activation of HSCs and, consequently, advancement of the disease. In addition, according to the data, there is an increased activity of CYP26A1, the enzyme responsible for RA degradation. RA signaling could also be deregulated. There is a need to explore the possible interaction between IL-17A and RA in the liver, to understand whether IL-17A-associated inflammation can be reversed by the action of active metabolites of vitamin A in humans, and to unravel the molecular mechanisms behind this likely regulation. Based on the immunopathobiology of human fibrogenesis, we can speculate that immune modulation of the IL-17A/RA axis could be a new important component of the very active therapeutic development of NASH and fibrotic disease.

**AUTHOR CONTRIBUTIONS**

DK-E, SP, and SL contributed to conception and design of the study. DK-E organized the database, analyzed and wrote the first draft of the manuscript, did the figures, and did the editing. SP and SL contributed to funding acquisition, supervision, and reviewing. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work is supported in part by Assistance Publique-Hôpitaux de Paris (AP-HP, France), by the Institut National de la Santé et de la Recherche Médicale (INSERM, France) and by Institut Pasteur (Paris, France). Daria M. Kartasheva-Ebertz received a PhD Fellowship from Assistance Publique-Hôpitaux de Paris (AP-HP, France).

**REFERENCES**

1. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver Cirrhosis Mortality in 187 Countries Between 1980 and 2010: A Systematic Analysis. *BMJ Med* (2014) 12:145. doi: 10.1161/s12916-014-0145-x
2. Asrani SK, Devabhaktuni H, Eaton J, Kamath PS. Burden of Liver Diseases in the World. *J Hepatol* (2019) 70:151–71. doi: 10.1016/j.jhep.2018.09.014
3. Han AL. Association Between Non-Alcoholic Fatty Liver Disease and Dietary Habits, Stress, and Health-Related Quality of Life in Korean Adults. *Nutrients* (2020) 12:1555. doi: 10.3390/nu12061555
4. Hallsworth K, Adams LA. Lifestyle Modification in NAFLD/NASH: Facts and Figures. *JHEP Rep* (2019) 1:468–79. doi: 10.1016/j.jhepr.2019.10.008
5. Doherty DG. Immunity, Tolerance and Autoimmunity in the Liver: A Comprehensive Review. *J Autoimmun* (2016) 66:60–75. doi: 10.1016/j.jaut.2015.08.020
6. Dixon Lj, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer Cells in the Liver. *Compr Physiol* (2013) 3:785–97. doi: 10.1002/cphy.c120026
7. Jenne CN, Kubes P. Immune Surveillance by the Liver. *Nat Immunol* (2013) 14:996–1006. doi: 10.1038/nl1256
8. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, et al. Autophagy Releases Lipoxygen Lipid That Promotes Fibrogenesis by Activated Hepatic Stellate Cells in Mice and in Human Tissues. *Gastroenterology* (2012) 142:938–46. doi: 10.1053/j.gastro.2011.12.044
9. Friedman SL, Roll FJ. Isolation and Culture of Hepatic Lipocytes, Kupffer Cells, and Sinusoidal Endothelial Cells by Density Gradient Centrifugation With Stractan. *Anal Biochem* (1987) 161:207–18. doi: 10.1016/0003-2697 (87)90673-7
10. Stine JG, Wentworth BJ, Zimmert A, Rinella ME, Loomba R, Caldwell SH, et al. Systematic Review With Meta-Analysis: Risk of Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis Without Cirrhosis Compared to Other Liver Diseases. *Aliment Pharmacol Ther* (2018) 48:696–703. doi: 10.1111/apt.14937
11. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin-17 Producing CD4+ Effector T Cells Develop Via a Lineage Distinct From the T Helper Type 1 and 2 Lineages. *Nat Immunol* (2005) 6:1123–32. doi: 10.1038/nilt25
12. Zhang J-Y, Zhang Z, Lin F, Zou Z-S, Xu R-N, Jin L, et al. Interleukin-17-Producing CD4+ T Cells Increase With Severity of Liver Damage in Patients With Chronic Hepatitis B. *Hepatology* (2010) 51:81–91. doi: 10.1002/hep.23273
13. Lemmers A, Moreno C, Gustot T, Marechal R, Degré D, Demetter P, et al. The interleukin-17 Pathway is Involved in Human Alcoholic Liver Disease. *Hepatology* (2009) 49:646–57. doi: 10.1002/hep.22680
14. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, et al. Interleukin-17 Signaling in Inflammatory, Kupffer Cells, and Hepatic Stellate Cells Exacerbates Liver Fibrosis in Mice. *Gastroenterology* (2012) 143:765–776.e3. doi: 10.1053/j.gastro.2012.05.049
15. Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, et al. IL-17A Plays a Critical Role in the Pathogenesis of Liver Fibrosis Through Hepatic Stellate Cell Activation. *J Immunol* (2013) 191:1835–44. doi: 10.4049/jimmunol.1203013
16. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille J, et al. The Orphan Nuclear Receptor RORgammat Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells. *Cell* (2006) 126:1211–33. doi: 10.1016/j.cell.2006.07.035
17. Kondo T, Takata H, Matsuki F, Takiguchi M. Cutting Edge: The Orphan Nuclear Receptor RORgammat Directs the Differentiation of Tissue-Homing Properties. *J Immunol* (2009) 182:1794–8. doi: 10.4049/jimmunol.0801347
18. Billerbeck E, Kang Y-H, Walker L, Lockstone H, Grafmueller S, Fleming V, et al. Analysis of CD161 Expression on Human CD8+ T Cells by FACSCaliber: A New Distinct Functional Subset With Tissue-Homing Properties. *Proc Natl Acad Sci* (2010) 107:3006–11. doi: 10.1073/pnas.091439107
24. Lafdil F, Miller AM, Ki SH, Gao B. Th17 Cells and Their Associated
22. Gaffen SL. Structure and Signalling in the IL-17 Receptor Superfamily.
27. Yuan S, Zhang S, Zhuang Y, Zhang H, Bai J, Hou Q. Interleukin-17
30. Veldhoen M. Interleukin 17 is a Chief Orchestrator of Immunity.
33. Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W,
37. Xie M-H, Aggarwal S, Ho W-H, Foster J, Zhang Z, Stinson J, et al.
46. Seo G-Y, Jang Y-S, Kim J, Choe J, Han H-J, Lee J-M, et al. Retinoic Acid Acts
51. Bono MR, Tejon G, Flores-Santibañez F, Fernandez D, Rosemblatt M,
56. Aggarwal S, Ghilardi N, Xie M-H, de Sauvage FJ, Gurney AL. Interleukin-23
60. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickenshees H,
64. Lafdil F, Miller AM, Ki SH, Gao B. Th17 Cells and Their Associated
72. Gaffen SL. Structure and Signalling in the IL-17 Receptor Superfamily.
78. Bosteen MH, Tritsaris K, Hansen AJ, Dissing S. IL-17A Potentiates TNf- 
82. Chen K, Eddens T, Treejyo-Nunez G, Way EE, Elsegeyny W, Ricks DM, et al.
86. Yuan S, Zhang S, Zhang H, Bai J, Hou Q. Interleukin-17 Stimulates Stats3-Mediated Endothelial Cell Activation for Neutrophil Recruitment. 
90. Veldhoen M. Interleukin 17 is a Chief Orchestrator of Immunity.
94. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al.
100. Liang Y, Pan H-F, Ye D-Q. IL-17A-Producing CD8(+)T Cells as Therapeutic
104. Liang Y, Pan H-F, Ye D-Q. IL-17A-Producing CD8(+)T Cells as Therapeutic
108. Taylor PR, Roy S, Leal SM, Sun Y, Howell SJ, Cobb BA, et al. Activation of 
112. Taylor PR, Roy S, Leal SM, Sun Y, Howell SJ, Cobb BA, et al. Activation of 
116. Taylor PR, Roy S, Leal SM, Sun Y, Howell SJ, Cobb BA, et al. Activation of 
120. Lafdil F, Miller AM, Ki SH, Gao B. Th17 Cells and Their Associated
124. Gaffen SL. Structure and Signalling in the IL-17 Receptor Superfamily.
128. Yuan S, Zhang S, Zhuang Y, Zhang H, Bai J, Hou Q. Interleukin-17
132. Yuan S, Zhang S, Zhuang Y, Bai J, Hou Q. Interleukin-17 Stimulates Stats3-Mediated Endothelial Cell Activation for Neutrophil Recruitment. 
136. Veldhoen M. Interleukin 17 is a Chief Orchestrator of Immunity.
140. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al.
144. Liang Y, Pan H-F, Ye D-Q. IL-17A-Producing CD8(+)T Cells as Therapeutic
148. Lafdil F, Miller AM, Ki SH, Gao B. Th17 Cells and Their Associated
152. Gaffen SL. Structure and Signalling in the IL-17 Receptor Superfamily.
156. Yuan S, Zhang S, Zhuang Y, Zhang H, Bai J, Hou Q. Interleukin-17 Stimulates Stats3-Mediated Endothelial Cell Activation for Neutrophil Recruitment. 
160. Veldhoen M. Interleukin 17 is a Chief Orchestrator of Immunity.
164. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al.
168. Liang Y, Pan H-F, Ye D-Q. IL-17A-Producing CD8(+)T Cells as Therapeutic
Kartasheva-Ebertz et al. Retinoic Acid, IL-17A, and IL-22 in Liver Fibrosis

58. Muscic D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid. *Science* (2007) 317:256–60. doi: 10.1126/science.1145697

59. Schambach F, Schupp M, Lazar MA, Reiner SL. Activation of Retinoic Acid-Receptor-Alpha Favours Regulatory T Cell Induction At the Expense of IL-17-Secreting T Helper Cell Differentiation. *Eur J Immunol* (2007) 37:2396–9. doi: 10.1002/eji.200737621

60. Martin JC, Béroui G, Heslan M, Chauvin C, Utriraen I, Aumeunier A, et al. Interleukin-22 Binding Protein (IL-22BP) is Constitutively Expressed by a Subset of Conventional Dendritic Cells and is Strongly Induced by Retinoic Acid. *Mucosal Immunol* (2014) 7:101–13. doi: 10.1038/mi.2013.28

61. Xiao S, Jin H, Korn T, Lim H, Oukka M, Lim B, et al. Retinoic Acid Increases Foxp3+ Regulatory T Cells and Inhibits Development of Th17 Cells by Enhancing TGF-beta-driven Smad3 Signaling and Inhibiting IL-6 and IL-23 Receptor Expression. *J Immunol* (2008) 181:4049–54. doi: 10.4049/jimmunol.181.4.20277

62. Ashla AA, Hoshikawa Y, Tsuchiya H, Hashiguchi K, Enjoji M, Nakamuta M, et al. Genetic Analysis of Expression Profile Involved in Retinoid Metabolism in non-Alcoholic Fatty Liver Disease. *Hepatol Res* (2010) 40:594–604. doi: 10.1111/j.1872-034X.2010.00646.x

63. Bord P, Desmarchelier C. Genetic Variations Associated With Vitamin A Status and Vitamin A Bioavailability. *Nutrients* (2017) 9(5):236. doi: 10.3390/nn903S246

64. Carlsson B, Linden D, Brodin G, Liljeblad M, Bursell M, Sorensen T, et al. Review Article: The Emerging Role of Genetics in Precision Medicine for Patients With non-Alcoholic Steatohepatitis. *Aliment Pharmacol Ther* (2020) 51:1305–20. doi: 10.1111/apt.151738

65. Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM, et al. Pnpla3 I148M Variant Inhibits Inflammation and IL-23 Receptor Expression. *Int Immunol* (2018) 30:594–401. doi: 10.4049/intimunol.30.4.017

66. Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM, et al. Pnpla3 I148M Variant Inhibits Inflammation and IL-23 Receptor Expression. *Int Immunol* (2018) 30:594–401. doi: 10.4049/intimunol.30.4.017

67. Mondul A, Mancina RM, Merlo A, Dongiovanni P, Rametta R, Montalcini L, et al. Metabolic Syndrome and IL-22 Ameliorates Liver Fibrogenesis by Attenuating Hepatic Stellate Cell Activation and Downregulating the Levels of Inflammatory Cytokines. *J Immunol* (2012) 188:6547–59. doi: 10.4049/jimmunol.1112712

68. Su W, Mao Z, Liu Y, Zhang X, Zhang W, Gustafsson J-A, et al. Role of HSD17B13 in the Liver Physiology and Pathophysiology. *Mol Cell Endocrinol* (2019) 489:119–25. doi: 10.1016/j.mce.2018.10.014

69. Abdul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. Protein-Truncating Hsd17b13 Variant and Protection From Chronic Liver Disease. *N Engl J Med* (2018) 378:1096–106. doi: 10.1056/NEJMoa1712191

70. Hu Z, Luo D, Mao J, Liu M, Zhao Y, Li L. IL-17 Activates the IL-6/STAT3 Signaling Pathway in the Proliferation of Hepatoblastoma Cells. *Cancer Lett* (2020) 45:2379–90. doi: 10.10111/j.1872-034X.2021.001574

71. Pirola CJ, Valenti L, Motta BM, Pingitore P, Hedfalk K, Mancina RM, et al. Pnpla3 I148M Variant Influences Circulating Retinol in Adults With Nonalcoholic Fatty Liver Disease or Obesity. *J Nutr* (2015) 145:1687–91. doi: 10.3945/jn.115.192633

72. Su W, Mao Z, Liu Y, Zhang X, Zhang W, Gustafsson J-A, et al. Role of HSD17B13 in the Liver Physiology and Pathophysiology. *Mol Cell Endocrinol* (2019) 489:119–25. doi: 10.1016/j.mce.2018.10.014

73. Parvis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular Carcinomas in Patients With Metabolic Syndrome Often Develop Without Significant Liver Fibrosis: A Pathological Analysis. *Hepatology* (2009) 50:1851–9. doi: 10.1002/hep.22734

74. Dhamija E, Paul SB, Kedia S. Non-Alcoholic Fatty Liver Disease Associated With Hepatocellular Carcinoma: An Increasing Concern. *Indian J Med Res* (2019) 149–199. doi: 10.4103/ijmrijm.1456_17

75. Parvis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular Carcinomas in Patients With Metabolic Syndrome Often Develop Without Significant Liver Fibrosis: A Pathological Analysis. *Hepatology* (2009) 50:1851–9. doi: 10.1002/hep.22734

76. Bataller R, Brenner DA. Liver Fibrosis. *J Clin Invest* (2005) 115:209–18. doi: 10.1172/jci200524228

77. Bataller R, Brenner DA. Liver Fibrosis. *J Clin Invest* (2005) 115:209–18. doi: 10.1172/jci200524228
96. Ni YH, Huo LJ, Li TT. [Effect of interleukin-22 on Proliferation and Activation of Hepatocyte Stellate Cells Induced by Acetalddehyde and Related Mechanism]. Zhonghua Gansu Zong Bing Za Zhi (2017) 25:9–14. doi: 10.3760/ cma.j.issn.1007-3418.2017.01.004

97. Zhang X-W, Mi S, Li Z, Zhou J-C, Xie J, Hua F, et al. Antagonism of Interleukin-17A Ameliorates Experimental Hepatic Fibrosis by Restoring the IL-10/STAT3-suppressed Apoptosis in Hepatocytes. Oncotarget (2017) 8:9922–34. doi: 10.18632/oncotarget.14266

98. Tedesco D, Thapa M, Chin CY, Ge Y, Gong M, Li J, et al. Alterations in Intestinal Microbiota Lead to Production of interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease. Gastroenterology (2018) 154:2178–93. doi: 10.1053/j.gastro.2018.02.016

99. Tang Y, Biao Z, Zhao L, Liu Y, Liang S, Wang Q, et al. interleukin-17 Exacerbates Hepatic Steatosis and Inflammation in non-Alcoholic Fatty Liver Disease. Clin Exp Immunol (2011) 166:281–90. doi: 10.1111/j.1365-2249.2011.04471.x

100. Shen T, Chen X, Li Y, Tang X, Jiang X, Yu C, et al. Interleukin-17A Exacerbates High-Fat Diet-Induced Hepatic Steatosis by Inhibiting Fatty Acid β-Oxidation. Biochim Biophys Acta (BBA) - Mol Basis Dis (2017) 1863:1510–8. doi: 10.1016/j.bbadis.2017.01.027

101. Harley IT, Stankiewicz TE, Giles DA, Softic S, Flick LM, Cappelletti M, et al. HER2 and HER3 Signaling Alters the Progression of Nonalcoholic Fatty Liver Disease. J Hepatology (2014) 59:1830–9. doi: 10.1002/hep.26746

102. Gills DA, Moreno-Fernandez ME, Stankiewicz TE, Cappelletti M, Hupper SS, Iwakura Y, et al. Regulation of Inflammation by IL-17A and IL-17F Modulates Non-Alcoholic Fatty Liver Disease Pathogenesis. PloS One (2016) 11:e0149783. doi: 10.1371/journal.pone.0149783

103. Her Z, Tan JHL, Lim Y-S, Tan SY, Chan XY, Tan WWS, et al. interleukin-17 Mediates Liver Steatosis and Progression of chronic Fatty Liver Disease. J Hepatology (2018) 59:1331–40. doi: 10.1016/j.jhep.2018.03.022

104. Wang L, Chen S, Xu K. interleukin-17 Expression is Correlated With hepatitis B Virus Infection. J Viral Hepat (2013) 20:144–51. doi: 10.1111/j.1365-3156.2012.01846.x

105. Zhang H, Yan X, Yang C, Zhan Q, Fu Y, Luo H, et al. interleukin-17a Promotes Hepatocellular Carcinoma via Upregulation of the Tgf-β Receptor on Hepatocyte Stellate Cells in a Jnk-Dependent Manner. J Immunol (2014) 193:3925–33. doi: 10.4049/jimmunol.1400861

106. Zhou Y, Wu P-W, Yuan X-W, Li J, Shi X-L. Interleukin-17A Inhibits Cell Autophagy Under Starvation and Promotes Cell Migration Via TAB2/TAB3-p38 Mitogen-Activated Protein Kinase Pathways in Hepatocellular Carcinoma. Eur Rev Med Pharmacol Sci (2016) 20:250–63.

107. Lodder J, Denais T, Chobert M-N, Wan J, El-Benna J, Padvlisky J-M, et al. Macrophage Autophagy Protects Against Liver Fibrosis in Mice. Autophagy (2015) 11:1280–92. doi: 10.1080/15548627.2015.1058473

108. Su S-B, Qin S-Y, Xian X-L, Huang F-F, Huang Q-L, Zhang Di H-J, et al. Interleukin-22 Regulating Kupffer Cell Polarization Through STAT3/Erk Akt Crosstalk Pathways to Exertuate Liver Fibrosis. Life Sci (2021) 264:11677. doi: 10.1016/j.lfs.2020.116677

109. Harada K, He X, Xiang M, Kim S-J, Ma J, et al. interleukin-22 Ameliorates Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets. Hepatology (2020) 72:412–29. doi: 10.1002/hep.31031

110. Rolla S, Alchera E, Iamarino B, Valente G, Cappello P, et al. The Balance Between IL-17 and IL-22 Produced by Liver-Infiltrating T-helper Cells Critically Controls NASH Development in Mice. Clin Sci (Lond) (2013) 120:193–203. doi: 10.1042/CS20130405

111. Hamaguchi M, Okamura T, Fukuda T, Nishida K, Yoshimura Y, Hashimoto Y, et al. Group 3 Innate Lymphoid Cells Protect Steatohepatitis From High-Fat Diet Induced Toxicity. Front Immunol (2021) 12:648754. doi: 10.3389/fimmu.2021.648754

112. Zhao J, Zhang Z, Luan Y, Zhou J, Sun Y, Li Y, et al. Pathological Functions of interleukin-22 in Chronic Liver Inflammation and Fibrosis With Hepatitis B Virus Infection by Promoting T Helper 17 Cell Recruitment. Hepatology (2014) 59:1331–42. doi: 10.1002/hep.26916

113. Sertorio M, Hou X, Carmo RF, Cabantous S, Abdelwahed M, et al. interleukin-22 and interleukin-22 Binding Protein (IL-22BP) Regulate Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C Virus and Schistosomiasis Infections. Hepatology (2015) 61:1321–31. doi: 10.1002/hep.27269

114. Wu L-Y, Liu S, Liu Y, Guo C, Li H, Li W, et al. Up-Regulation of interleukin-22 Mediates Liver Fibrosis Via Activating Hepatic Stellate Cells in Patients With Hepatitis C. Clin Immunol (2015) 158:77–87. doi: 10.1016/j.clim.2015.03.003

115. Simionon PL, Wehrmann F, Roark CL, Born WK, O’Brien RL, Fontenot AP, γδ T Cells Protect Against Lung Fibrosis Via IL-22. J Exp Med (2010) 207:2239–53. doi: 10.1084/jem.20100061

116. Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y, et al. interleukin-22 Promotes Human Hepatocellular Carcinoma by Activation of STAT3. Hepatology (2011) 54:9900–9. doi: 10.1002/hep.24486

117. Xiang X, Gui H, King NJ, Cole L, Wang H, Xie Q, et al. IL-22 and non-ELR-CXC Chemokine Expression in Chronic Hepatitis B Virus-Infected Liver. Immunol Cell Biol (2012) 90:611–9. doi: 10.1038/icb.2011.79

118. Kronenberger B, Rudloff I, Bachmann M, Brunner F, Kapper L, Filmann N, et al. interleukin-22 Predicts Severity and Death in Advanced Liver Cirrhosis: A Prospective Cohort Study. BMC Med (2012) 10:102. doi: 10.1186/1741-7015-10-102

119. Chen M, Liu J, Yang W, Ling W. Lipopolysaccharide Mediates Hepatic Stellate Cell Activation by Regulating Autophagy and Retinoic Acid Signaling. Autophagy (2017) 13:1813–27. doi: 10.4161/aut.354627.2017.1336550

120. Testerink N, Ajat M, Houweling M, Brouwers JF, Pully VV, van Manen H-J, et al. Replacement of Retinyl Esters by Polyunsaturated Triacylglycerol Species in Lipid Droplets of Hepatic Stellate Cells During Activation. PloS One (2012) 7(4):e34945. doi: 10.1002/hep.26746

121. Grumet L, Eichmann TO, Taschner U, Zäerler KA, Leopold C, Moustafa T, et al. Lysosomal Acid Lipase Hydrolyzes Retinyl Ester and Affects Retinoid Turnover. J Biol Chem (2016) 291:17977–87. doi: 10.1074/jbc.M116.724054
GLOSSARY

| Acronym | Description                                    |
|---------|------------------------------------------------|
| HCC     | hepatocellular carcinoma                      |
| NASH    | non-alcoholic steatohepatitis                 |
| NAFLD   | non-alcoholic fatty liver disease             |
| RA      | retinoic acid                                 |
| HSCs    | hepatic stellate cells                        |
| PRRs    | pattern recognition receptors                 |
| TLR4    | toll-like receptor 4                          |
| LPS     | lipopolysaccharide                            |
| LSEC    | liver sinusoidal endothelial cells            |
| TGF-β   | transforming growth factor                    |
| ECM     | extracellular matrix                          |
| PD-L1   | programmed death-ligand 1                    |
| Th17    | T helper 17 lymphocytes                       |
| Tc17    | T cytotoxic 17 lymphocytes                    |
| LTs     | lymphocytes T                                |
| NKT     | natural killer T cell                         |
| ILC3s   | type 3 innate lymphoid cells                  |
| MALTs   | mucosal associated invariant T cells          |
| GM-CSF  | granulocyte colony-stimulating factor         |
| EAE     | experimental autoimmune encephalomyelitis     |
| BDL     | bile-duct ligation                            |
| RADLH   | retinaldehydrogenases                         |
| RBP4    | retinol binding protein 4                     |
| RARα, β, γ | retinoic acid receptors                    |
| RXRα, β, γ | retinoid X receptors                  |
| TNFα    | tumor necrosis factor α                       |
| IRF-4   | interferon regulatory factor 4                |
| AKR1B10 | aldo-keto reductase family 1 member B10       |
| ALDH1A  | aldehyde dehydrogenase 1 family member A     |
| BCO1    | beta-caroten oxygenase 1                     |
| SCARB1  | scavenger-receptor class B 1                 |
| PNPLA3  | patatin-like phospholipase domain-containing 3|
| HSD17B13| 17β-Hydroxysteroid dehydrogenase type 13     |
| WT      | wild type                                     |
| CCl4    | carbon tetrachloride                          |
| PDGF    | platelet derived growth factor                |
| INF-4   | interferon 4                                  |
| G-CSF   | granulocyte colony-stimulating factor         |
| ConA    | concanavalin A                                |
| MMP     | metalloproteinase                             |
| TIMP    | tissue inhibitor of metalloproteinases        |
| MDSCs   | myeloid-derived suppressor cells              |
| VEGF    | vascular endothelial growth factor            |
| UDCA    | ursodeoxycholic acid                          |